Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension

Abstract

The effects of sustained renin inhibition by repeated administration of enalkiren (A-64662), the novel dipeptide renin inhibitor, were evaluated in a randomized, double-blind, placebo-controlled, parallel-group study of 32 inpatients (eight per group) with essential hypertension who were maintained on a diet containing 60 meq/day sodium. Three different dosage regimens of enalkiren were studied: 1) 1.2 mg/kg quotid., 2) of mg/kg q.i.d., and 3) 0.1 mg/kg q. i.d. Each patient received an intravenous infusion every 6 hours for 1 week. Placebo inftisions were used to mimic the 4 times/day dosing schedule. Blood pressure was measured periodically via 24-hour automated monitoring equipment. Mean plasma renin activity in the patient groups ranged from 1.58 to 2.68 ng angiotensin 1/ml/hr. Plasma renin activity was promptly suppressed in all groups receiving enalkiren. Prolonged duration of plasma renin activity suppression (≥24 hours) was demonstrated after the administration of 1.2 mg/kg enalkiren. The 03 mg/kg q.i.d. and 1.2 mg/kg quotid. regimens produced statistically significant reductions (p≤0.05) in systolic and diastolic blood pressures with clear evidence of persistent antihypertensive activity for 12 hours or more when compared with the placebo group. Despite relatively large reductions in mean systolic and diastolic blood pressure, mean pulse rates were essentially unchanged. The prolonged reduction in blood pressure with enalkiren without evidence of tachyphylaxis after 1 week of treatment suggests that renin inhibitors may emerge as useful therapeutic agents for the treatment of hypertension. © 1990 American Heart Association, Inc.